Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747987 | 0.86 | SMN1; SMN2 (0.50) | MEN1KMT2A | |
| SCHEMBL27889747 | 0.81 | CFTR (0.43) | TSHRKMT2A | |
| SCHEMBL2746949 | 0.80 | MAOB (0.48) | TSHRMEN1KMT2ALMNAPLA2G2A | |
| SCHEMBL248534 | 0.80 | ALDH1A1 (0.42) | TSHRMEN1KMT2ADYRK1APLA2G2A | |
| SCHEMBL5753078 | 0.77 | MAOB (0.45) | TSHRMEN1KMT2ALMNAPLA2G2A | |
| SCHEMBL250804 | 0.75 | NR3C1 (0.48) | MEN1KMT2AMTNR1AMTNR1BRXFP1 | |
| SCHEMBL28316742 | 0.75 | LMNA (0.47) | MEN1KMT2ALMNA | |
| SCHEMBL7003535 | 0.74 | NR3C1 (0.49) | TSHRMTNR1AMTNR1BACHEMAPK1 | |
| SCHEMBL24895093 | 0.72 | LMNA (0.55) | MEN1KMT2ALMNAAKR1C3AKR1C2 | |
| SCHEMBL10390929 | 0.72 | LMNA (0.59) | LMNAAKR1C3AKR1C2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106205-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106205-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100137590-A1 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137590-A1 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137590-A1 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | NQO2, NAT1, QPCT | TSHR 4250/4885MEN1 4854/4885KMT2A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.